彌散性血管內(nèi)凝血【】2課件_第1頁
彌散性血管內(nèi)凝血【】2課件_第2頁
彌散性血管內(nèi)凝血【】2課件_第3頁
彌散性血管內(nèi)凝血【】2課件_第4頁
彌散性血管內(nèi)凝血【】2課件_第5頁
已閱讀5頁,還剩69頁未讀 繼續(xù)免費閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)

文檔簡介

彌散性血管內(nèi)凝血

Chapter11中山醫(yī)學院病理生理教研室鄧宇斌彌散性血管內(nèi)凝血

Chapter11中山醫(yī)學院病理生理1

DIC一、DIC原因和發(fā)病機制二、促進DIC發(fā)生發(fā)展的因素(誘發(fā)困素)三、DIC的分期和分型四、DIC的功能代謝變化(病理生理變化)五、DIC防治的病理生理基礎(chǔ)DIC2第一節(jié)概述1.血液的凝固與抗凝流動性血液運輸載體方向性內(nèi)(Ⅻ)凝血系統(tǒng)凝血外(Ⅲ)血小板:粘聚釋第一節(jié)概述1.血液的凝固與抗凝3凝↑/抗凝↓

→栓塞失衡凝↓/抗凝↑

→出血傾向2.DIC的概念出血病因微血栓后休克致凝繼發(fā)纖溶亢進果栓塞溶血>120種病:感染、腫瘤、產(chǎn)科意外凝↑/抗凝↓→栓塞4Introduction

DICischaracterizedbytheactivationofthecoagulationsystemwithresultantconsumptionofavarietyofcoagulationproteinsandplatelets,whichresultsinhemorrhagicdiathesisandischemicinjurytovarioustissues.IntroductionDICisc51.BloodCoagulation

Itispropagatedbyanenzymaticeventstermedcoagulationcascade.ContactfactorsandtheintrinsicpathwayTissuefactorandextrinsicpathway

1.BloodCoagulation62.Fibrinolysis

Itistheresultoftheactionofplasmin,aproteolyticenzymeproducedfromaninertplasmaprecursor(plasminogen)bytheactionofvarioussubstancestermedplasminogenactivators.

2.Fibrinolysis7HumoralplasminogenactivatorsTissueplasminogenactivatorsFibrinorfibrinogendegradationproductsFDP(Significantbiologicalactivity)FragmentsX,YandE(potentantithrombins)FragmentsYandD(inhibitfibrinpolymerization)Humoralplasminogenactivators8

ⅡaⅡaⅢaPCAPCTM+Ⅱ滅活PS(+)C4bC4bPS(-)

9

纖溶

FDP

酶ATPC

APCTM+Ⅱa

PSPGI2VECTM

10第二節(jié)DIC的病因發(fā)病學一、發(fā)病原因及機理1.VEC廣泛受損

⑴原因感染炎癥、免疫損傷(抗磷脂綜合征)高低溫、放射損傷缺血缺氧酸中毒第二節(jié)DIC的病因發(fā)病學一、發(fā)病原因及機理11EtiologyofDIC1.acuteDIC(1)septicemia(2)severetrauma(3)obstetricaccidents(4)shock2.subacuteDIC(1)malignanttumors(2)retaineddeadfetus3.chronicDIC

(1)gianthemangioma(2)systemiclupuserythematosus(SLE)EtiologyofDIC1.acuteDIC12⑵機理膠原暴露凝↑VEC釋放Ⅲ受損合成PGI2↓→TXA2↑抗凝↓表達TM↓→APC↓⑵機理132.血細胞大量受損⑴RBC受損感染:瘧疾原因:溶血G6PDase↓:蠶豆病免疫損傷:異型輸血紅細胞素(Ⅲ)機理:釋ADP→P聚集2.血細胞大量受損14⑵WBC激活或受損壞死白血病細胞→釋Ⅲ原因化療受損機理炎癥激活→合成、釋Ⅲ(內(nèi)毒素、補體、LC、P、Ag-Ab)⑵WBC激活或受損15

⑶P激活或受損原發(fā)性:免疫損傷(抗P抗體抗磷脂抗體)繼發(fā)性:DIC粘(GPⅠb-膠原)聚(GPⅡb/Ⅲa-fg)TXA2等P聚、血管收縮機理PF1~11提供“反應面”

ⅩⅡⅨa-Ca2+-ⅧaⅩa-Ca2+-ⅡaPF3PF3⑶P激活或受損163.大量致凝物質(zhì)入血腫瘤細胞

⑴Ⅲ壞死(包括產(chǎn)科意外)組織細胞

⑵帶負電顆粒物質(zhì)(內(nèi)毒素)→Ⅻa胰蛋白酶

⑶其它絲氨酸蛋白水解酶→Ⅱa蝰蛇毒3.大量致凝物質(zhì)入血17PathogenesisofDIC

1.extensivedamageofvascularendothelialcells

Intrinsicclottingcascade2.severetissueinjury

ExtrinsicclottingreactionPathogenesisofDIC1.extensiv183.excessivedestructionofthecirculatingbloodcells

Generationofprocoagulant-activesubstances

Intravascularcoagulation4.otherthromboplasticmaterialsenteringthebloodActivationofclottingsystemthroughthecontactofbloodwithanabnormalsurface3.excessivedestructionofthe19theneteffectsaresummarizedasfollows:1.lossofplasmafibrinogenasitisconsumedbytheclottingprocessandbytheactionofplasma.2.lossofotherclottingfactorsnotablyⅤ,ⅧandⅫ,astheyareusedupduringtheoperationoftheclottingcascade.3.fallintheplateletcount,astheplateletsaggregateandleavethecirculation.4.appearanceoffibrindegradationproducts,asplasminactsonitssubstrates.theneteffectsaresummarized20

二、誘因與發(fā)生機理消除致凝物質(zhì)功能血液凝血活性↑/抗凝活性↓

1.單核吞噬細胞系統(tǒng)功能內(nèi)毒素血癥、糖皮質(zhì)激素、脾消除功能↓:致凝物、Ⅱa、凝纖產(chǎn)物

二、誘因與發(fā)生機理21

2.肝功能嚴重障礙滅活活化凝血因子↓合成AT-Ⅲ、PC↓枯否細胞吞噬功能↓

3.血液的高凝狀態(tài)凝血活性↑-凝血物質(zhì)↑:懷孕、腫瘤、應激抗纖溶:胎盤、藥抗凝活性↓抗肝素:H+AT、PC、TM等↓

4.血流郁滯2.肝功能嚴重障礙22PredisposingfactorstoDIC1.impairmentoftheclearancemechanism.2.hypercoagulablestate.3.disorderofmicrocirculation.PredisposingfactorstoDIC1.i23第三節(jié)DIC的分期及分型高凝期

分期

消耗性低凝期繼發(fā)性纖溶亢進期急性按發(fā)病速度亞急性

慢性

代償型按代償情況失代償型過度代償型第三節(jié)DIC的分期及分型24TypesofDIC1.acuteDICMultisidebleedingdiathesisThromboticcomplicationsusuallySeverebleedingleadtoshockandsevereischemicchangeinorgans2.subacuteDICRarelybleedingTheevidenceofDICcanbedetectedbylaboratoryexaminations3.chronicDICTypesofDIC25StageofDIC1.hypercoagulablestage2.hypocoagulablestage3.secondaryfibrinolyticstageStageofDIC1.hypercoagulable26第四節(jié)臨床表現(xiàn)1.出血凝血物質(zhì)消耗性↓酶:破壞凝血因子繼發(fā)性纖溶亢進ⅡaFDP抗凝:競爭性抑制ⅢaP聚血管壁受損及溶栓第四節(jié)臨床表現(xiàn)1.出血27ConsequencesofDIC

1.disturbanceofcoagulation----bleeding(1)theconsumptionofclottingfactorsandplatelets(2)theactivationoffibrinolyticsystem(3)theproductionoffibrindegradationproducts(FDPs)ConsequencesofDIC1.disturba282.休克

出血回心血量↓微血栓阻斷通路CO↓心泵功能↓:心肌DICBP↓右心后負荷↑:肺DIC外周阻力↓:四個酶系統(tǒng)激活

↓A、B肽擴血管物質(zhì)↑FDP(通透性↑)激肽C3a、C5a

292.disturbanceofcirculation----shockMicrothromobusincapillariesandvenulesBloodreturningdecreaseCardiacmuscledamageCardiacoutputandbloodvolumereduceEffectivecirculatingbloodvolumedecreaseHypotension2.disturbanceofcirculation--30

3.栓塞微血栓器官功能BP↓供血障礙

4.溶血:微血管病性溶血性貧血

3.栓塞313.ischemictissuedamage----dysfunctionofmultipleorgansRenalinsufficiencyAcuteadrenalfailurePituitarynecrosisAdultoracuterespiratorydistresssyndrome(ARDS)Convulsionandcoma3.ischemictissuedamage----dy324.microangiopathichemolyticanemia(MHA)characteristicmorphologicabnormalityoftheredbloodcellsTwistedcells,crenatedcells,triangularcells,helmet-shapedcells,andmicrospherocytesareseenonthebloodsmear.4.microangiopathichemolytica33Pathophysiologicalbasisoflaboratorydiagnosis1.detectionofplateletcountanditsfunction2.determinationofclottingfactors3.determinationofactivityoffibrinolysis(1)thrombintimetest(TT)(2)plasmaprotamineparacoagulationtest(3Ptest)(3)euglobulinlysistime(ETL)Pathophysiologicalbasisofla34PrinciplesofmanagementofDIC1.treatmentofthecausativedisease2.clottingfactorreplacement3.anticoagulationtherapy4.othermodesoftherapyPrinciplesofmanagementofDI35TheEndgoodbyeTheEndgoodbye365678abcdeghijklnopqrtuvwxzABCDEGHIJKMNOPQSTUVWYZ#!$%*()-+12345789abcefgxzABCDFGHIJKMNOPQSTUVWYZ#!$%*()-+12345789abdefghiklmnoqrstuwxyzABDEFGHJKLMNPQRSTUWXYZ#$%&*(-+012456789bcdefhijklnopqrsuvwxyABCDEGHIJKLNOPQRTUVWXZ#!$%*()-+02345689abcefghijlmnoprstuvxyzABCEnopqrtuvwxzABCDEGHIJKMNOPQSTUV245678abcdeghijklnopqrtuvwxzABCDFGHIJKMNOPQSTUVWYZ#!$%*()-+12345789abcefghiklmnoqrstuwxyzABDEFGHJKLMNPQRSTUWXYZ#$%&*(-+01UVWYZ#!$&*()-012345789abdefghjklmnoqrstuwxyzACDEFGIJKLMNPQRSTVWXYZ!$%&*(-+01245678abcdefhijklnopqrtuvwxzABCDEGHIJKMNOPQSTUVWXZ#!$%bcdeghijklnopqrtuvwxzABCDEGHIJKMNOPyzBCDEFGIJKLMOPQRSUVWXYZ!$%&*)-+01345679abcdeghijkmnopqstuvwxzABCDFGHIJLMNOPQSTUVWYZ#!$&*()-012345789abdefghjklmnoqrstuwxyzACDEFGHJKLMNPQRSTVWXYZ!$%&*(-+01245678abcdefhijklnopqrtuvwxyABCDEGHIJKMN&*(-+01245678abcdefhijklnopqrtuvwxzABCDEGHIJKMNOPQSTUVWXZ#!$%*()-+12345689abcefghiklmnoqrstuvxyzABDEFGHJKLMNOQRSTUWXYZ#$%&*(-+012356789bcdefhijklmopqrsuvwxyABCDEFHIJKLNOPQRTU12356789bcdefhijklmopqrsuvwxyAByzABDEFGHJKLMNOQRSTUWXYZ#$%&*()+012356789bcdefgijklmopqrsuvwxyABCDEFHIJKLNOPQRTUVWXY#!$%&()-+02345679abcdfghijlmnoprstuvwyzABCEFGHqrsuvwxyABCDEGHIJKMNOPQRTUVWXZ#!$%*()-+02345689abcefghijlmnoprstuvxyzABDEFGHIKLMNOQRSTUWXYZ#!%&*()+012356789acdefgijklmopqrsuvwxyzBCDEFHIJKLNOPQRSUVWXY#!$%&()-+02345679abcdfghijlmnopqsJKLNOPQRTUVWXY#!$%&()-+02345679abcdfghijlmnopqstuvwyzABCEFGHIKLMNOPRSTUVXYZ#!%&*()-012346789acdefghjklmnpqrstvwxyzBCDEFGIJKLMOPQRSUVWXYZ!$%&*)-+01345678abcdeghijkmnopqstuvwOPQRSUVWXY#!$%&*)-+01345679abcdeghijkmnopqstuvwxzABCDFGHIJLMNOPRSTUVWYZ#!$&*()-012345789abdefghjklmnoqrstuwxyzACDEFGIJKLMNPQRSTVWXYZ!$%&*(-+01245678abcdefhijklnopqrtuvefghjklmnpqrstvwxyzACDEFGIJKLMOPQRSUVWXYZ!$%&*)-+013456lnopqrtuvwxyABCDEGHIJKMNOPQRTUVWXZ#!$%*()-+02345689abcefghiklmnoprstuvxyzABDEFGHIKLMNOQRSTUWXYZIJKMNOPQSTUVWYZ#!$%*()-+12345789abcefghiklmnoqrstuwxyzABDEFGHJKLMNPQRSTUWXYZ#$%&*(-+012356789bcdefhijklnopqrsuvwxyABCDEGHIJKLNOPQRTUVWXZ#!$%&()-+02345689abcefghyABCDEGHIJKMNOPQRTUVWXZ#!$%*()-+02345689abcefghijlmnoprstuvxyzABDEFGHIKLMNOQRSTUWXYZ#!%&*()+012356789acdefgijklmopqrsuvwxyzBCDEFHIJKLNOPQRSUVWXY#!$%&()-+gijklmopqrsuvwxyzBCDEFHIJKLNOPQRTUVWXY#!$%&()-+02345679abcdfghijlmnopqstuvwyzABCEFGHIKLMNOPRSzABCDFGHIJLMNOPRSTUVWYZ#!$&*()-012346789abdefghjklmnpqrstuwxyzACTUVXYZ#!$&*()-012346789abdefghjklmnpqrstvwxyzACDEFGIJKLMOPQRSTVWXYZ!$%&*)-+01245678abcdeghijkmnopqrtuvwxzABCDFGHIJKMNOPQSTUVWYZ#!$%*()-+12345789abdefghiklmnFGHIJKMNOPQSTUVWYZ#!$&*()-+12345789abdefghiklmnoqrstuwxyzABDEFGHJKLMNPQRSTVWXYZ#$%&*(-+012456789bcdefhijklnopqrtuvwxyABCDEGHIJKMNOPQRTUVWFGIJKLMOPQRSTVWXYZ!$%&*)-+01245678abcdeghijklnopqrtuvwLNOPQRTUVWXZ#!$%&()-+02345689abcefghijlmnoprstuvxyzABCEFGHIKLMNOQRSTUVXYZ#!%&*()+012356789acdef-+12345689abcefghiklmnoqrstuvxyzABDEFGHJKLMNOQRSTUWXYZ#$%&*()+012356789bcdefhijklmopqrsuvwxyABCDEFHIJKLNOPQRTUVWXY#!$%&()-+02345mopqrsuvwxyABCDEFHIJKLNOPQRTUVWXZ#!$%&()-+02345689abcdfghijlmnoprstuvxyzABCEFGHIKLMNOQRSTUVXYZ#!%&*()+012346789acdefgijklmopqrstLMNOQwyzABCEFGHIKLMNOPRSTUVXYZ#!%&*()-012346789acdefgijklmnpqrstvwxyzBCDEFGIJKLMOPQRSUVWXYZ!$%&*)-+01345679abcdeghijkmnopqstuvMOPQRSUVWXY#!$%&*)-+01345679abcdeghijkmnopqstuvwxzABCDFGHIJLMNOPRSTUVWYZ#!$&*()-012345789abdefghjklmnoqrstuwxyzACDEFGIJKLMNPQRSTVWXYZ!$LMNOPRSTUVXYZ#!%&*()-012346789acdefghjklmnpqrstvwxyzACDEFGIJKLMO%&*(-+012456789bcdefhijklnopqrtuvwxyABCDEGHIJKMNOPQRTUVWXZ#!$%*()-+02345689abcefghikBCDEGHIJKMNOPQSTUVWXZ#!$%*()-+12345689abcefghiklmnoprstuvxyzABDEFGHJKLMNOQRSTUWXYZ#$%&*()+012356789bcdefgijklmopqrsuvwxyABCDEFHIJKtuwxyzABDEFGHJKLMNPQRSTVWXYZ#$%&*(-+012456789bcdefhijklnopqrsuvwxyABCDEGHIJKMN$%&()-+01345679abcdfghijlmnopqstuvwyzABCEFGHIJLMNOPRSTUVXYZ#!$&*(dfghijlmnopqstuvwyzABCEFGHIKLMNOPRSTUVXYZ#!%&*()-012346789acdefghjklmnpqrstvwxyzBCDEFGIJKLMOPQRSUVWXYZ!$%&*)-+0134567#!%&*()+012356789acdefgijklmopqrstvwxyzBCDEFHIJKLNOPQRSUVWXY#!$%&()-+01345679abcdfghijkmnCDFGHIJKMNOPQSTUVWYZ#!$%*()-+12345789abdefghi1345679abcdeghijkmnopqstuvwyzABCDFGHIJLMNOPRSTUVWYZ#!$&*()-012345789abdefghjklmnpqrstuwxyzACDEFGIJKLMNPQRSTVWXYZ!$%&*(-+0124567pqrstuwxyzACDEFGIJKLMOPQRSTVWXYZ!$%&*)-+01245678abcdeghijklnopqrtuvwxzABCDFGHIJKM!$%&()-+02345689abcefghijlmnoprstuvxfhijklnopqrtuvwxzABCDEGHIJKMNOPQSTUVWXZ#!$%*()-+12345689abcefghiklmnoqrstuvxyzABDEFGHJKLMNOQRSTUWXYZ#$%&*()+012356789bcduvxyzABDEFGHJKLMNOQRSTUWXYZ#$%&*(-+012356789bcdefhijklmopqrsuvwxyABCDEGHIJKLNOPQR)-+01345679abcdeghijkmnopqstcdefgijklmopqrsuvwxyzBCDEFHIJKLNOPQRTUVWXY#!$%&()-+02345679abcdfghijlmnoprstuvwyzABCEFGHIKLMNOPRSTUVXYZ#!%&*()-012346789acdefgyzABCEFGHIKLMNOPRSTUVXYZ#!%&*()+012346789acdefgijklmnpqrstvwxyzBCDEFGIJqrstvwxyzACDEFGIJKLMOPQRSTVWXYZ!$%&*)-+01345678abcdeghijkmnopqrtuvMOPQRSUVWXYZ!$%&*)-+01345678abcdeghijkmnopqrtuvwxzABCDFGHIJLMNOPQSTUVWYZ#!$&*()-+12345789abdefghiklmnoqrstuwxyzACDEFGHJ#!$&*()-012345789abdefghjklmno5789abcefghiklmnoqrstuwxyzABDEFGHJKLMNPQRSTUWXYZ#$%&*(-+012356789bcduwxyzABDEFGHJKLMNPQRSTVWXYZ#$%&*(-+012456789bcdefhijklnopqrsuvwxyABCDEGHIJKMNOPQRTUVWXZ#!$%*()-+02345689abce)-+01245678abcdeghijklnopqrtuJKLNOPQRTUVWXZ#!$%&()-+023456895678abcdeghijklnopqrtuvwxzABCD37彌散性血管內(nèi)凝血

Chapter11中山醫(yī)學院病理生理教研室鄧宇斌彌散性血管內(nèi)凝血

Chapter11中山醫(yī)學院病理生理38

DIC一、DIC原因和發(fā)病機制二、促進DIC發(fā)生發(fā)展的因素(誘發(fā)困素)三、DIC的分期和分型四、DIC的功能代謝變化(病理生理變化)五、DIC防治的病理生理基礎(chǔ)DIC39第一節(jié)概述1.血液的凝固與抗凝流動性血液運輸載體方向性內(nèi)(Ⅻ)凝血系統(tǒng)凝血外(Ⅲ)血小板:粘聚釋第一節(jié)概述1.血液的凝固與抗凝40凝↑/抗凝↓

→栓塞失衡凝↓/抗凝↑

→出血傾向2.DIC的概念出血病因微血栓后休克致凝繼發(fā)纖溶亢進果栓塞溶血>120種?。焊腥?、腫瘤、產(chǎn)科意外凝↑/抗凝↓→栓塞41Introduction

DICischaracterizedbytheactivationofthecoagulationsystemwithresultantconsumptionofavarietyofcoagulationproteinsandplatelets,whichresultsinhemorrhagicdiathesisandischemicinjurytovarioustissues.IntroductionDICisc421.BloodCoagulation

Itispropagatedbyanenzymaticeventstermedcoagulationcascade.ContactfactorsandtheintrinsicpathwayTissuefactorandextrinsicpathway

1.BloodCoagulation432.Fibrinolysis

Itistheresultoftheactionofplasmin,aproteolyticenzymeproducedfromaninertplasmaprecursor(plasminogen)bytheactionofvarioussubstancestermedplasminogenactivators.

2.Fibrinolysis44HumoralplasminogenactivatorsTissueplasminogenactivatorsFibrinorfibrinogendegradationproductsFDP(Significantbiologicalactivity)FragmentsX,YandE(potentantithrombins)FragmentsYandD(inhibitfibrinpolymerization)Humoralplasminogenactivators45

ⅡaⅡaⅢaPCAPCTM+Ⅱ滅活PS(+)C4bC4bPS(-)

46

纖溶

FDP

酶ATPC

APCTM+Ⅱa

PSPGI2VECTM

47第二節(jié)DIC的病因發(fā)病學一、發(fā)病原因及機理1.VEC廣泛受損

⑴原因感染炎癥、免疫損傷(抗磷脂綜合征)高低溫、放射損傷缺血缺氧酸中毒第二節(jié)DIC的病因發(fā)病學一、發(fā)病原因及機理48EtiologyofDIC1.acuteDIC(1)septicemia(2)severetrauma(3)obstetricaccidents(4)shock2.subacuteDIC(1)malignanttumors(2)retaineddeadfetus3.chronicDIC

(1)gianthemangioma(2)systemiclupuserythematosus(SLE)EtiologyofDIC1.acuteDIC49⑵機理膠原暴露凝↑VEC釋放Ⅲ受損合成PGI2↓→TXA2↑抗凝↓表達TM↓→APC↓⑵機理502.血細胞大量受損⑴RBC受損感染:瘧疾原因:溶血G6PDase↓:蠶豆病免疫損傷:異型輸血紅細胞素(Ⅲ)機理:釋ADP→P聚集2.血細胞大量受損51⑵WBC激活或受損壞死白血病細胞→釋Ⅲ原因化療受損機理炎癥激活→合成、釋Ⅲ(內(nèi)毒素、補體、LC、P、Ag-Ab)⑵WBC激活或受損52

⑶P激活或受損原發(fā)性:免疫損傷(抗P抗體抗磷脂抗體)繼發(fā)性:DIC粘(GPⅠb-膠原)聚(GPⅡb/Ⅲa-fg)TXA2等P聚、血管收縮機理PF1~11提供“反應面”

ⅩⅡⅨa-Ca2+-ⅧaⅩa-Ca2+-ⅡaPF3PF3⑶P激活或受損533.大量致凝物質(zhì)入血腫瘤細胞

⑴Ⅲ壞死(包括產(chǎn)科意外)組織細胞

⑵帶負電顆粒物質(zhì)(內(nèi)毒素)→Ⅻa胰蛋白酶

⑶其它絲氨酸蛋白水解酶→Ⅱa蝰蛇毒3.大量致凝物質(zhì)入血54PathogenesisofDIC

1.extensivedamageofvascularendothelialcells

Intrinsicclottingcascade2.severetissueinjury

ExtrinsicclottingreactionPathogenesisofDIC1.extensiv553.excessivedestructionofthecirculatingbloodcells

Generationofprocoagulant-activesubstances

Intravascularcoagulation4.otherthromboplasticmaterialsenteringthebloodActivationofclottingsystemthroughthecontactofbloodwithanabnormalsurface3.excessivedestructionofthe56theneteffectsaresummarizedasfollows:1.lossofplasmafibrinogenasitisconsumedbytheclottingprocessandbytheactionofplasma.2.lossofotherclottingfactorsnotablyⅤ,ⅧandⅫ,astheyareusedupduringtheoperationoftheclottingcascade.3.fallintheplateletcount,astheplateletsaggregateandleavethecirculation.4.appearanceoffibrindegradationproducts,asplasminactsonitssubstrates.theneteffectsaresummarized57

二、誘因與發(fā)生機理消除致凝物質(zhì)功能血液凝血活性↑/抗凝活性↓

1.單核吞噬細胞系統(tǒng)功能內(nèi)毒素血癥、糖皮質(zhì)激素、脾消除功能↓:致凝物、Ⅱa、凝纖產(chǎn)物

二、誘因與發(fā)生機理58

2.肝功能嚴重障礙滅活活化凝血因子↓合成AT-Ⅲ、PC↓枯否細胞吞噬功能↓

3.血液的高凝狀態(tài)凝血活性↑-凝血物質(zhì)↑:懷孕、腫瘤、應激抗纖溶:胎盤、藥抗凝活性↓抗肝素:H+AT、PC、TM等↓

4.血流郁滯2.肝功能嚴重障礙59PredisposingfactorstoDIC1.impairmentoftheclearancemechanism.2.hypercoagulablestate.3.disorderofmicrocirculation.PredisposingfactorstoDIC1.i60第三節(jié)DIC的分期及分型高凝期

分期

消耗性低凝期繼發(fā)性纖溶亢進期急性按發(fā)病速度亞急性

慢性

代償型按代償情況失代償型過度代償型第三節(jié)DIC的分期及分型61TypesofDIC1.acuteDICMultisidebleedingdiathesisThromboticcomplicationsusuallySeverebleedingleadtoshockandsevereischemicchangeinorgans2.subacuteDICRarelybleedingTheevidenceofDICcanbedetectedbylaboratoryexaminations3.chronicDICTypesofDIC62StageofDIC1.hypercoagulablestage2.hypocoagulablestage3.secondaryfibrinolyticstageStageofDIC1.hypercoagulable63第四節(jié)臨床表現(xiàn)1.出血凝血物質(zhì)消耗性↓酶:破壞凝血因子繼發(fā)性纖溶亢進ⅡaFDP抗凝:競爭性抑制ⅢaP聚血管壁受損及溶栓第四節(jié)臨床表現(xiàn)1.出血64ConsequencesofDIC

1.disturbanceofcoagulation----bleeding(1)theconsumptionofclottingfactorsandplatelets(2)theactivationoffibrinolyticsystem(3)theproductionoffibrindegradationproducts(FDPs)ConsequencesofDIC1.disturba652.休克

出血回心血量↓微血栓阻斷通路CO↓心泵功能↓:心肌DICBP↓右心后負荷↑:肺DIC外周阻力↓:四個酶系統(tǒng)激活

↓A、B肽擴血管物質(zhì)↑FDP(通透性↑)激肽C3a、C5a

662.disturbanceofcirculation----shockMicrothromobusincapillariesandvenulesBloodreturningdecreaseCardiacmuscledamageCardiacoutputandbloodvolumereduceEffectivecirculatingbloodvolumedecreaseHypotension2.disturbanceofcirculation--67

3.栓塞微血栓器官功能BP↓供血障礙

4.溶血:微血管病性溶血性貧血

3.栓塞683.ischemictissuedamage----dysfunctionofmultipleorgansRenalinsufficiencyAcuteadrenalfailurePituitarynecrosisAdultoracuterespiratorydistresssyndrome(ARDS)Convulsionandcoma3.ischemictissuedamage----dy694.microangiopathichemolyticanemia(MHA)characteristicmorphologicabnormalityoftheredbloodcellsTwistedcells,crenatedcells,triangularcells,helmet-shapedcells,andmicrospherocytesareseenonthebloodsmear.4.microangiopathichemolytica70Pathophysiologicalbasisoflaboratorydiagnosis1.detectionofplateletcountanditsfunction2.determinationofclottingfactors3.determinationofactivityoffibrinolysis(1)thrombintimetest(TT)(2)plasmaprotamineparacoagulationtest(3Ptest)(3)euglobulinlysistime(ETL)Pathophysiologicalbasisofla71PrinciplesofmanagementofDIC1.treatmentofthecausativedisease2.clottingfactorreplacement3.anticoagulationtherapy4.othermodesoftherapyPrinciplesofmanagementofDI72TheEndgoodbyeTheEndgoodbye735678abcdeghijklnopqrtuvwxzABCDEGHIJKMNOPQSTUVWYZ#!$%*()-+12345789abcefgxzABCDFGHIJKMNOPQSTUVWYZ#!$%*()-+12345789abdefghiklmnoqrstuwxyzABDEFGHJKLMNPQRSTUWXYZ#$%&*(-+012456789bcdefhijklnopqrsuvwxyABCDEGHIJKLNOPQRTUVWXZ#!$%*()-+02345689abcefghijlmnoprstuvxyzABCEnopqrtuvwxzABCDEGHIJKMNOPQSTUV245678abcdeghijklnopqrtuvwxzABCDFGHIJKMNOPQSTUVWYZ#!$%*()-+12345789abcefghiklmnoqrstuwxyzABDEFGHJKLMNPQRSTUWXYZ#$%&*(-+01UVWYZ#!$&*()-012345789abdefghjklmnoqrstuwxyzACDEFGIJKLMNPQRSTVWXYZ!$%&*(-+01245678abcdefhijklnopqrtuvwxzABCDEGHIJKMNOPQSTUVWXZ#!$%bcdeghijklnopqrtuvwxzABCDEGHIJKMNOPyzBCDEFGIJKLMOPQRSUVWXYZ!$%&*)-+01345679abcdeghijkmnopqstuvwxzABCDFGHIJLMNOPQSTUVWYZ#!$&*()-012345789abdefghjklmnoqrstuwxyzACDEFGHJKLMNPQRSTVWXYZ!$%&*(-+01245678abcdefhijklnopqrtuvwxyABCDEGHIJKMN&*(-+01245678abcdefhijklnopqrtuvwxzABCDEGHIJKMNOPQSTUVWXZ#!$%*()-+12345689abcefghiklmnoqrstuvxyzABDEFGHJKLMNOQRSTUWXYZ#$%&*(-+012356789bcdefhijklmopqrsuvwxyABCDEFHIJKLNOPQRTU12356789bcdefhijklmopqrsuvwxyAByzABDEFGHJKLMNOQRSTUWXYZ#$%&*()+012356789bcdefgijklmopqrsuvwxyABCDEFHIJKLNOPQRTUVWXY#!$%&()-+02345679abcdfghijlmnoprstuvwyzABCEFGHqrsuvwxyABCDEGHIJKMNOPQRTUVWXZ#!$%*()-+02345689abcefghijlmnoprstuvxyzABDEFGHIKLMNOQRSTUWXYZ#!%&*()+012356789acdefgijklmopqrsuvwxyzBCDEFHIJKLNOPQRSUVWXY#!$%&()-+02345679abcdfghijlmnopqsJKLNOPQRTUVWXY#!$%&()-+02345679abcdfghijlmnopqstuvwyzABCEFGHIKLMNOPRSTUVXYZ#!%&*()-012346789acdefghjklmnpqrstvwxyzBCDEFGIJKLMOPQRSUVWXYZ!$%&*)-+01345678abcdeghijkmnopqstuvwOPQRSUVWXY#!$%&*)-+01345679abcdeghijkmnopqstuvwxzABCDFGHIJLMNOPRSTUVWYZ#!$&*()-012345789abdefghjklmnoqrstuwxyzACDEFGIJKLMNPQRSTVWXYZ!$%&*(-+01245678abcdefhijklnopqrtuvefghjklmnpqrstvwxyzACDEFGIJKLMOPQRSUVWXYZ!$%&*)-+013456lnopqrtuvwxyABCDEGHIJKMNOPQRTUVWXZ#!$%*()-+02345689abcefghiklmnoprstuvxyzABDEFGHIKLMNOQRSTUWXYZIJKMNOPQSTUVWYZ#!$%*()-+12345789abcefghiklmnoqrstuwxyzABDEFGHJKLMNPQRSTUWXYZ#$%&*(-+012356789bcdefhijklnopqrsuvwxyABCDEGHIJKLNOPQRTUVWXZ#!$%&()-+02345689abcefghyABCDEGHIJKMNOPQRTUVWXZ#!$%*()-+02345689abcefghijlmnoprstuvxyzABDEFGHIKLMNOQRSTUWXYZ#!%&*()+012356789acdefgijklmopqrsuvwxyzBCDEFHIJKLNOPQRSUVWXY#!$%&()-+gijklmopqrsuvwxyzBCDEFHIJKLNOPQRTUVWXY#!$%&()-+02345679abcdfghijlmnopqstuvwyzABCEFGHIKLMNOPRSzABCDFGHIJLMNOPRSTUVWYZ#!$&*()-012346789abdefghjklmnpqrstuwxyzACTUVXYZ#!$&*()-012346789abdefghjklmnpqrstvwxyzACDEFGIJKLMOPQRSTVWXYZ!$%&*)-+01245678abcdeghijkmnopqrtuvwxzABCDFGHIJKMNOPQSTU

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
  • 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論